PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
December 4, 2025Clinical TrialsOpen Access

Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases

View Full Paper
Ask AI
Bookmark
Share

Authors

CGChristine GirgesAKAlexa KingGAGrace Auld

Discussion

Loading...

Member takes

Overview

Observational analysis found mild depressive symptoms worsen self-reported outcomes in Parkinson’s disease, suggesting implications for clinical trials.

Key Points

  • Self-reported outcomes indicate participants with mild depressive symptoms report worse disease impact.
  • 32.5% of Parkinson’s patients had mild-to-moderate depressive symptoms and reported poorer outcomes.
  • Assessment using Patient Health Questionnaire and Unified Parkinson’s Disease Rating Scale captures depression's effect.
  • Findings highlight the need to consider depressive symptoms when analyzing neurodegenerative disease trials.

Cite This Study

Girges et al. (2025) studied this question.

synapsesocial.com/papers/6930dc81ea1aef094cca2474https://doi.org/10.1177/17407745251387571
View Full Paper
Ask AI
Bookmark
Share